Rifampin

C. diff Risk

NA

Oral Bioavailability

NA

Approximate Cost

Dosing

Should not be used as monotherapy Tuberculosis 600 mg IV/PO every 24 hr Endocarditis 300 mg IV/PO every 8 hr Prosthetic joint/Osteomyelitis infections 450 mg IV/PO every 12 hr

General Information

Common Usage

Mycobacterial infections, Brucellosis, osteomyelitis, and prosthetic joint infections due to Staphyloccocus aureus (always use in combination with other agents).

Drug Monitoring

Lab

  • Basline and periodic LFTs

Clinical

  • Multiple drug interactions

Adverse Effects

  • Nausea/vommiting, diarrhea

  • abnormal liver enzymes

  • rash (Steven-Johnson syndrome)

  • myopathy

Major Interactions

Inducer of many CYP enzymes including 3A4, and 2C9. Review patients medications carefully.

Additional Information

  • Should never bee used as monotherapy

  • May discolor bodily secretions (yellow-reddish). Caution in contact lens wearers.

Pharmacology

Antimicrobial class: Antimycobacterial

Pregnancy category: C

Average serum half life: 3-4 hr

Lung penetration: Therapeutic

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Route of Elimination: Feces